Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle

Michael J. Heiferman, Mohammad R. Salabat, Michael B. Ujiki, Matthew J. Strouch, Eric C. Cheon, Richard B. Silverman, David J. Bentrem

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Survival of patients with pancreatic cancer remains poor due to inadequate chemotherapeutic options. Sansalvamide A, a cyclic depsipeptide produced by a marine fungus, has demonstrated significant anticancer activity. We previously observed antiproliferative effects in a series of sansalvamide A analogs in pancreatic cancer cells, one of which was further evaluated in this study. Two human pancreatic cancer cell lines (AsPC-1 and CD18) were incubated with increasing concentrations (10-50 μM) of the sansalvamide analog. Cell proliferation was then measured by thymidine incorporation and cell counting, and cell cycle analysis was determined by flow cytometry. Western blot analysis was used to evaluate expression of cyclin D1, cdk4, cdk6, cyclin E, cyclin A, cdk2, and p21. Sansalvamide caused G1 phase cell cycle arrest in both cell lines, and Western blot analyses demonstrated up-regulation of p21, down-regulation of cyclins D1, E, and A, and cdk4, consistent with G 0/G1 cell cycle arrest. Cumulatively the results show that Sansalvamide A attenuates pancreatic cancer cell growth and represents a potential anticancer therapy.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalAnticancer research
Volume30
Issue number1
StatePublished - Jan 1 2010

    Fingerprint

Keywords

  • Cell cycle arrest
  • Pancreatic cancer
  • Sansalvamide A

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this